Find Vamorolone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 13209-41-1, Vamorolone [usan], Vbp-15 free alcohol, 17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione, 16alpha-methyl-9,11-dehydro prednisolone, 8xp29xmb43
Molecular Formula
C22H28O4
Molecular Weight
356.5  g/mol
InChI Key
ZYTXTXAMMDTYDQ-DGEXFFLYSA-N
FDA UNII
8XP29XMB43

Vamorolone
Vamorolone is under investigation in clinical trial NCT03439670 (A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)).
1 2D Structure

Vamorolone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one
2.1.2 InChI
InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1
2.1.3 InChI Key
ZYTXTXAMMDTYDQ-DGEXFFLYSA-N
2.1.4 Canonical SMILES
CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1(C(=O)CO)O)C)C
2.1.5 Isomeric SMILES
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C
2.2 Other Identifiers
2.2.1 UNII
8XP29XMB43
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Vbp15 Compound

2.3.2 Depositor-Supplied Synonyms

1. 13209-41-1

2. Vamorolone [usan]

3. Vbp-15 Free Alcohol

4. 17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione

5. 16alpha-methyl-9,11-dehydro Prednisolone

6. 8xp29xmb43

7. (8s,10s,13s,14s,16r,17r)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-one

8. Chembl2348780

9. Vbp15

10. (8s,10s,13s,14s,16r,17r)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3h-cyclopenta[a]phenanthren-3-one

11. Unii-8xp29xmb43

12. Vbp 15

13. Einecs 236-177-8

14. 16

15. A-methyl-9,11-dehydro Prednisolone

16. Vamorolone [inn]

17. Vamorolone (usan/inn)

18. Vamorolone [who-dd]

19. Vbp15vbp15

20. Schembl143459

21. Gtpl9247

22. Amy7535

23. Dtxsid60927527

24. Bdbm50432396

25. Zinc33650317

26. Db15114

27. Pregna-1,4,9(11)-triene-3,20-dione, 17,21-dihydroxy-16-methyl-, (16.alpha.)-

28. Hy-109017

29. Cs-0030515

30. Dexamethasone Impurity E [ep Impurity]

31. D11000

32. 16.alpha.-methyl-9,11-dehydroprednisolone

33. J-006120

34. Q27089127

35. 17,21-dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene- 3,20-dione

36. 17.alpha.,21-dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione

37. Delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 356.5 g/mol
Molecular Formula C22H28O4
XLogP32.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass356.19875937 g/mol
Monoisotopic Mass356.19875937 g/mol
Topological Polar Surface Area74.6 Ų
Heavy Atom Count26
Formal Charge0
Complexity775
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of Duchenne muscular dystrophy


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty